|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Long C, Jiang L, Wei F, Ma C, Zhou H, Yang
S, Liu X and Liu Z: Integrated miRNA-mRNA analysis revealing the
potential roles of miRNAs in chordomas. PLoS One. 8:e666762013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsu SH, Wang B, Kota J, Yu J, Costinean S,
Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, et al: Essential
metabolic, anti-inflammatory, and anti-tumorigenic functions of
miR-122 in liver. J Clin Invest. 122:2871–2883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang Y, Xue JL, Shen Q, Chen J and Tian L:
MicroRNA-7 inhibits tumor growth and metastasis by targeting the
phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
Hepatology. 55:1852–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rawlings-Goss RA, Campbell MC and Tishkoff
SA: Global population-specific variation in miRNA associated with
cancer risk and clinical biomarkers. BMC Med Genomics. 7:532014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pencheva N, Tran H, Buss C, Huh D,
Drobnjak M, Busam K and Tavazoie SF: Convergent multi-miRNA
targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis
and angiogenesis. Cell. 151:1068–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin JC, Jin XL, Zhang X, Piao YS and Liu
SP: Effect of OSW-1 on microRNA expression profiles of hepatoma
cells and functions of novel microRNAs. Mol Med Rep. 7:1831–1837.
2013.PubMed/NCBI
|
|
10
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.
|
|
11
|
Zhang Y, Zhang L, Zhang G, Li S, Duan J,
Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma
metastasis: Prospective role of ezrin. Tumour Biol. 35:5055–5059.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Y, de Castro LF, Shin MH, Dubois W,
Yang HH, Jiang S, Mishra PJ, Ren L, Gou H, Lal A, et al: p53 loss
increases the osteogenic differentiation of bone marrow stromal
cells. Stem Cells. 33:1304–1319. 2015. View Article : Google Scholar
|
|
13
|
Diller L, Kassel J, Nelson CE, Gryka MA,
Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B,
et al: p53 functions as a cell cycle control protein in
osteosarcomas. Mol Cell Biol. 10:5772–5781. 1990.PubMed/NCBI
|
|
14
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like Forkhead transcription factors mediate cell-cycle
regulation by Ras and PKB through p27kip1. Nature. 404:782–787.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng Z, Ding M, Ni J, Song D, Huang J and
Wang J: MiR-142 acts as a tumor suppressor in osteosarcoma cell
lines by targeting Rac1. Oncol Rep. 33:1291–1299. 2015.
|
|
16
|
Hu Y, Xu S, Jin W, Yi Q and Wei W: Effect
of the PTEN gene on adhesion, invasion and metastasis of
osteosarcoma cells. Oncol Rep. 32:1741–1747. 2014.PubMed/NCBI
|
|
17
|
Song D, Ni J, Xie H, Ding M and Wang J:
DNA demethylation in the PTEN gene promoter induced by
5-azacytidine activates PTEN expression in the MG-63 human
osteosarcoma cell line. Exp Ther Med. 7:1071–1076. 2014.PubMed/NCBI
|
|
18
|
Shen L, Chen XD and Zhang YH: MicroRNA-128
promotes proliferation in osteosarcoma cells by downregulating
PTEN. Tumour Biol. 35:2069–2074. 2014. View Article : Google Scholar
|
|
19
|
Yang YK, Xi WY, Xi RX, Li JY, Li Q and Gao
YE: MicroRNA-494 promotes cervical cancer proliferation through the
regulation of PTEN. Oncol Rep. 33:2393–2401. 2015.PubMed/NCBI
|
|
20
|
Zhang WL and Zhang JH: miR-181c promotes
proliferation via suppressing PTEN expression in inflammatory
breast cancer. Int J Oncol. 46:2011–2020. 2015.PubMed/NCBI
|
|
21
|
Hodakoski C, Fine B, Hopkins B and Parsons
R: Analysis of intracellular PTEN signaling and secretion. Methods.
77–78:164–171. 2015. View Article : Google Scholar
|
|
22
|
Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL,
Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, et al:
MicroRNA-144 promotes cell proliferation, migration and invasion in
nasopharyngeal carcinoma through repression of PTEN.
Carcinogenesis. 34:454–463. 2013. View Article : Google Scholar
|
|
23
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pencheva N, Tran H, Buss C, et al:
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent
melanoma metastasis and angiogenesis. Cell. 151:1068–1082. 2012.
View Article : Google Scholar : PubMed/NCBI
|
